What's in Epizyme, Inc.'s pipeline?

Epizyme, Inc. has 4 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Epizyme, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/epizyme-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Epizyme, Inc. — Portfolio Competitive Intelligence Brief

Epizyme, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Tazverik	tazemetostat	marketed	Methyltransferase Inhibitor	Polycomb protein EED	Oncology	2020-01-01
Tazverik	TAZEMETOSTAT	marketed	Methyltransferase Inhibitor	Polycomb protein EED	Oncology	2020-01-01

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Epizyme, Inc.:

Cite this brief

Drug Landscape (2026). Epizyme, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/epizyme-inc. Accessed 2026-05-16.